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This thesis describes a quest to understand and use the phenomenon of revertant mosaicism for 
treatment of the heritable skin disease called epidermolysis bullosa (EB). EB is caused by mu-
tations in the dermal and epidermal proteins and is characterised by blistering of the skin and 
mucosa. 
In Chapter 1 of this thesis we describe the pathological mechanism behind EB, we introduce the 
phenomenon of revertant mosaicism and discuss current approaches to treat EB. At the moment 
there are 18 genes identified in which mutations may cause EB. The recent consensus divides 
EB in four major types and more than 30 subtypes depending on the level of blister formation, 
affected protein, disease severity and presence of extra cutaneous manifestations.  Moreover, a 
detailed overview of function of three proteins involved in the dermal epidermal junction, type 
XVII collagen (Col17), laminin-332 (lam-332) and type VII collagen (Col7) is given. Mutations in 
genes encoding Col17 and lam-332 cause junctional epidermolysis bullosa (JEB), while mutations 
in type VII collagen are responsible for the dystrophic variant of EB. At the moment no curative 
therapy is available for EB and the current approach to treat EB can be divided in three main 
groups: gene therapy, protein replacement and cell therapy. Gene therapy focuses on correction 
of the affected gene; protein replacement therapy aims at supplying the wild-type version of the 
affected protein, whereas cell therapy uses autologous or allogeneic cells to change the course of 
disease. The current state-of-the-art of those therapies is discussed in more detail in Chapter 1.   
This thesis focuses on a novel approach to treat EB using revertant mosaicism. Revertant mo-
saicism (RM) is a phenomenon in which there is a co-existence of affected cells containing a 
disease-causing mutation (mutant), and cells in which the mutation is naturally corrected to the 
wild-type phenotype (revertant) within one individual . That is why RM is often addressed to as 
‘natural gene therapy’. Since the first description of RM in a patient affected with Lesch-Nyhan 
syndrome in 1988, this phenomenon has been found in many other diseases, like Wiskott-Al-
drich Syndrom (WAS), Fanconi anemia and EB. There are different mechanisms described that 
can cause RM, like single base pair substitution or a second-side mutation. The full overview 
of those mechanisms can be found in Chapter 1. Within one individual many different correct-
ing mechanisms can be found, for example 38 different reversions were identified in a patient 
affected with WAS.
In the skin RM was first described in 1995 in a patient affected by the JEB subtype caused by 
mutations in the COL17A1 gene coding for the Col17 protein. Between affected skin areas on 
the patient’s arms healthy looking skin patches were found. Immunofluorescence staining of 
the skin biopsy taken from a skin patch showed presence of Col17, whereas the biopsy taken 
from the affected skin was negative for the protein. The molecular mechanism behind RM in this 
patient was found in 1997. In cells with normal Col17 expression one of the original mutations 
causing the disease disappeared due to a gene conversion. The presence of healthy skin patches 
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was named revertant mosaicism and healthy cells were called revertant. Since 1997, RM has 
been found in many JEB and DEB patients and it is believed that all patients affected by muta-
tions in COL17A1 have revertant skin patches. Presence of the healthy cells within an affected 
body is a unique opportunity for autologous cell therapy. Different methods of skin transplan-
tation have already been used to treat burn wounds and chronic wounds. Transplantation of 
revertant keratinocyte to expand the revertant skin area is the aim of revertant cell therapy.
In Chapter 2 we describe an attempt to increase revertant skin area in a Col17 deficient, JEB 
generalized intermediate (JEB-gen-intermed) patient. The patient was a compound homozygous 
for a maternal frame shift mutation in exon 18 (c.1601delA) and paternal nonsense mutation in 
exon 51 (c.3676C>T). This patient had multiple revertant skin patches and in some of them the 
following correction mechanism was identified, i.e. part of the paternal allele of COL17A1 con-
taining a healthy copy of exon 18 was moved to the maternal allele and covered the c.1601delA 
mutation resulting in one allele with a paternal mutation and one wild-type. From such a natu-
rally corrected revertant skin patch a skin biopsy was taken and cultured in vitro to acquire two 
6x7 cm epidermal sheets. The wound bed was prepared by adhesive tape stripping – an inno-
vative method that uses EB’s pathological mechanism of reduced adhesion in the lamina lucida. 
Briefly, an adhesive tape was placed on the patient’s thigh and small incisions were made around 
it. The lack of adhesion due to the mutations in COL17A1 resulted in removal of the epidermis 
when tape was pulled off. Skin grafts were placed on the prepared wound bed and the healing 
process was uneventful and successful.  Unfortunately, the functional test showed no reversion 
of EB phenotype and thus no expansion of revertant skin area. Analysis of the biopsy, cultured 
cells and epidermal grafts revealed that the percentage of revertant cells decreased from 50% 
in the biopsy to less than 3% in the graft. At that moment the reason for such a decrease was 
unknown.
Chapter 3 describes the animal model of the revertant cell therapy for EB. In this chapter we 
looked into survival of revertant cells during cell isolation, graft production and engraftment on 
immunodeficient mice. A biopsy from the same patient taken from the same revertant patch as 
in experiments described in Chapter 2 was used. We isolated keratinocytes and fibroblasts and 
assessed the percentage of the revertant cells after the first passage to be 40%. This percentage 
dropped to 25% and 20% after the second passage and in the cultured skin equivalent, respec-
tively. We grafted skin equivalents containing 20% of revertant cells on the immunodeficient 
mice and assessed the percentage of revertant area after 10 and 16 weeks. On both time-points 
20% of the cells was revertant meaning that long-term survival of revertant keratinocytes in 
vivo is possible. In Chapter 3 we also looked into the colony forming potential of revertant 
keratinocytes. We showed that revertant keratinocytes have a high ability to form colonies, but 
revertant colonies were smaller than mutant ones. This, together with the recently published 
work describing influence of Col17 on immunomodulation and NF-κB levels, gave us a basis to 
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formulate a theory about decrease of percentage of Col17 revertant cells during in vitro expan-
sion. This theory is discussed in more detail in Chapter 7.
Chapter 4 describes a different approach to revertant cell therapy, where in vitro expansion of 
revertant cells is omitted and naturally corrected skin is transplanted directly onto the acceptor 
site. We successfully treated a then 69-year-old male patient affected by JEB-gen-intermed due 
to homozygous c.628G>A mutations in the LAMB3 gene with revertant punch biopsy grafting. 
Multiple revertant patches on this patient’s body were earlier identified. Immunofluorescence on 
a biopsy from his mutant skin showed strongly reduced staining for laminin-332, while normal 
levels of laminin-332 were observed in the revertant patches. In 2012 this patient presented 
with multiple, persistent (>1 year) ulcers. We used an earlier identified revertant skin patch on 
his right shoulder as a donor site and harvested 73 punch biopsy specimens that were then 
placed in the wounds. All biopsies were accepted and wounds healed within 2 weeks. During 
the course of 18 months no blistering or ulcerations were observed in the treated areas. Skin 
biopsies from both donor and acceptor site showed re-epithelialisation with revertant epidermis 
expressing normal levels of laminin-322. Thus, a successful expansion of revertant skin area and 
application of revertant cells in therapy of EB were shown.
Revertant mosaicism is a source of naturally corrected cells for therapy as well as an interesting 
phenomenon that allows studying two genetically different cell populations within one body. 
In Chapter 5 we investigated why revertant skin patches in patients with revertant mosaicism 
and mutations in COL17A1 are hyperpigmented in contrast to their mutant skin. In a popula-
tion of 13 patients with EB and revertant mosaicism with mutations in COL17A1 (n=8), LAMB3 
(n=2) and COL7A1 (n= 3) the phenotype of affected (=mutant) and healthy (=revertant) skin 
was compared. The amount of pigment and density of melanocytes were identified in biopsies 
taken from mutant and revertant skin. There was a clinical difference in pigmentation in the 
COL17A1 group, which was not present in the other two groups. Further, more pigment in the 
Fontana-Masson staining and a significantly higher melanocyte density was found in Col17 re-
vertant skin versus Col17 mutant skin. In contrast, patients with mutations in LAMB3 showed a 
lower melanocyte density and amount of pigment in both revertant and mutant skin. Mutations 
in COL7A1 did not to have a correlation with the amount of pigment or density of melanocytes. 
In the study presented in Chapter 5 we concluded that pigmentation depends on Col17 and 
that lam-332 might have a negative influence on proliferation of melanocytes and therefore on 
pigmentation. How the proteins of the dermal-epidermal junction regulate the pigmentation 
and density of melanocytes is still unknown. Col17 seems however to have an important role in 
the inflammatory pathways, cell signalling and survival of melanocyte stem cells, while lam-332 




Many other hypotheses and possible improvements to expand the revertant area of the skin 
were investigated during work on this thesis. In Chapter 6 three selected experiments, that were 
perhaps not a direct step forward on the path to revertant cell therapy but are worth mention-
ing, are presented. First, an approach to select Col17 revertant keratinocytes involving differ-
ences in adhesion between Col17 positive and negative cells is described. Unfortunately, not 
only Col17 is responsible for adhesion to plastic and coatings such as lam-332 or type I collagen 
in keratinocytes and therefore we could not separate keratinocytes based on Col17 expression. 
Next, the successful sorting of living revertant and mutant Col17 cells with flow cytometry is 
shown using the 233 monoclonal antibody. Non-enzymatic detachment of keratinocytes was 
used in this method to preserve the extracellular domain of Col17 and allow immunofluores-
cence staining. This method allowed further in vitro culture of sorted cells. This is, however, not 
possible to apply in the clinical setting at the moment due to safety regulations.
In the second part of Chapter 6 we describe an attempt to establish a murine model for Col7 
revertant cell therapy based on a similar approach as presented in Chapter 3. A recessive dystro-
phic EB patient due to mutations in the COL7A1 gene had a revertant patch on her arm. From 
this patch a biopsy was taken, cells were isolated and skin equivalents were cultured. In the side 
samples only less then 10% of cells were revertant while in the biopsy taken previously from this 
patch 85% of the epidermis showed presence of Col7. Skin grafts were placed on the immu-
nodeficient mice and analysed with immunofluorescence after 10 and 16 weeks. No revertant 
cells could be found in the grafts meaning that we did not succeed in transplantation of healthy 
cells. Low numbers of naturally corrected cells in the original biopsy taken for cell isolation was 
a probable cause of the unsuccessful experiment. Col7 revertant cell therapy should be further 
studied with a biopsy containing a higher percentage of revertant keratinocytes.
The last experiment presented in Chapter 6 involves the same patient as described in Chapter 4. 
He underwent transplantation of non-cultured epidermal cells in suspension harvested from his 
revertant skin patch to treat a chronic leg ulcer. Impaired wound healing due to age and arterial 
obstruction had a negative influence on the procedure and complete re-epithelialization was not 
reached. We expected that some revertant cells were engrafted with this procedure, because 
a bridge dividing the ulcer in two smaller wounds was seen 6 weeks after the procedure and 
remained stable during the seven-month follow-up. A study of transplantation of non-cultured 
revertant cells in suspension with a controlled, well prepared acceptor site, will validate this 
technique for future usage.  
Chapter 7 of this thesis summarizes the findings of Chapters 2-6 and discusses advantages and 
disadvantages of revertant cell therapy as an approach to cure EB. Currently, treatment of limit-
ed skin areas with punch grafting is possible. In the near future we expect to use new techniques 
to transplant revertant cells with and without in vitro expansion, depending on the needs of the 
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patient. Chapter 7 also discusses the future use of induced pluripotent stem cell technology to 
produce a population of naturally corrected stem cells that could be used to treat EB locally (with 
skin grafts) and systemically (through infusion).
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